BioPharma Credit (LSE:BPCR) Beta: -0.2895 (As of Jul. 02, 2026)


LSE:BPCR BioPharma Credit PLC LSE:BPCR
49 GF Score
Price $0.96
GF Value $0.97
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is BioPharma Credit Beta?

BioPharma Credit LSE:BPCR +0.63% 49 Beta is -0.2895 as of Jul. 02, 2026. GuruFocus rates LSE:BPCR with a GF Score™ of 49/100 and a GF Value™ of $0.97 (Fairly Valued). The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-02), BioPharma Credit's Beta is -0.2895.


BioPharma Credit  (LSE:BPCR) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


BioPharma Credit Beta Related Terms


BioPharma Credit Beta Historical Data

* Premium members only.

The historical data trend for BioPharma Credit's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioPharma Credit Beta Chart

BioPharma Credit Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.12 0.37 0.10

BioPharma Credit Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.11 0.37 0.26 0.10

LSE:BPCR vs BLK, BX, KKR: Beta Comparison

For the Asset Management subindustry, BioPharma Credit's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioPharma Credit Beta vs Asset Management Industry

For the Asset Management industry and Financial Services sector, BioPharma Credit's Beta distribution charts can be found below:

* The bar in red indicates where BioPharma Credit's Beta falls into.


LSE:BPCR
49GF Score
BioPharma Credit PLC LSE:BPCR
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioPharma Credit Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.2895 mean?
BioPharma Credit (LSE:BPCR) has a Beta of -0.2895 as of Jul. 02, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for BioPharma Credit and its competitors.
Is BioPharma Credit's Beta too high?
BioPharma Credit's current Beta is -0.2895. Overall, BioPharma Credit has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's Beta compare to BLK and BX?
BioPharma Credit's Beta of -0.2895 can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for an Asset Management company?
A good Beta depends on the Asset Management industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for BioPharma Credit and its competitors. BioPharma Credit's current Beta is -0.2895. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Fairly Valued. The stock's GF Value™ is $0.97, compared to a current price of $0.96 — trading 1% below its estimated fair value. The current Beta is -0.2895. BioPharma Credit's overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current Beta is -0.2895 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?

Based on GuruFocus' analysis, BioPharma Credit stock appears to be undervalued. The current stock price of $0.96 is trading 1% below its estimated GF Value™ of $0.97. GuruFocus considers BioPharma Credit to be Fairly Valued.

Key valuation signals for LSE:BPCR:

  • Beta: -0.2895
  • GF Value™: $0.97 vs. price of $0.96 (1% below fair value)
  • GF Score™: 49/100 with 2 warning signs

No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioPharma Credit Business Description

Address c/o MUFG Corporate Governance Limited, 51 Lime Street, 19th Floor, London, GBR, EC3M 7DQ
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
49GF Score

Get the complete analysis for LSE:BPCR

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.96
Price
$0.97
GF Value